Z

Zymeworks
D

ZYME

11.480
USD
0.00
(0.00%)
مفتوح الان
حجم التداول
8,814
الربح لكل سهم
-2
العائد الربحي
-
P/E
-8
حجم السوق
799,269,653
أصول ذات صلة
A
ARCT
-0.800
(-6.25%)
12.010 USD
C
CRSP
-0.750
(-1.99%)
36.860 USD
I
INO
-0.06500
(-3.23%)
1.95000 USD
S
SLNO
2.390
(3.24%)
76.240 USD
V
VCEL
-0.370
(-0.89%)
41.040 USD
المزيد
الأخبار المقالات

العنوان: Zymeworks

القطاع: Healthcare
الصناعة: Biotechnology
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.